

WHO PHARMACOVIGILANCE INDICATORS: A PRACTICAL MANUAL FOR THE ASSESSMENT OF PHARMACOVIGILANCE SYSTEMS



World Health
Organization

WHO **pharmacovigilance** **indicators**

A practical manual for
the assessment
of pharmacovigilance
systems



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

WHO: pharmacovigilance indicators: a practical manual for the assessment of pharmacovigilance systems.

1.Pharmacovigilance. 2.Drug-Related Side Effects and Adverse Reactions – epidemiology. 3.Drug Monitoring. I.World Health Organization.

ISBN 978 92 4 150825 4

(NLM classification: QV 771)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by minimum graphics

Printed in France

Contents

Acknowledgements	v
Abbreviations	vi
How to use this manual	vii
1. Introduction	1
2. Pharmacovigilance indicators	4
2.1 Definition	4
2.2 Rationale and objectives of pharmacovigilance indicators	4
2.3 Characteristics of ideal pharmacovigilance indicators	5
2.4 Classification (type) of pharmacovigilance indicators	5
3. The context of WHO pharmacovigilance indicators	7
3.1 WHO strategy for monitoring a country's pharmaceutical situation	7
3.2 How the WHO pharmacovigilance indicators were developed	7
4. Categories of WHO pharmacovigilance indicators	9
4.1 Core pharmacovigilance indicators	9
4.2 Complementary indicators	12
4.3 Indicators for public health programmes	15
5. Data sources	16
5.1 Indicator format	16
6. Description of core indicators	18
6.1 Core structural indicators	18
6.2 Core process indicators	25
6.3 Core outcome or impact indicators	32
7. Description of indicators for a public health programme	41
References	53
Further reading	55
Annexes	57
Annex 1: Minimum requirements for a functional pharmacovigilance system	59
Annex 2: Background information	61
Annex 3: Assessment checklist	63

Acknowledgements

Special thanks are due to Ambrose Isah, University of Benin, Nigeria (Chairman, National Drug Safety Advisory Committee, Nigeria), for leading the work on identifying the candidate indicators for pharmacovigilance systems and for preparing the first draft of this publication. The contributions from the national pharmacovigilance centres of countries participating in the WHO Programme for International Drug Monitoring were critical to the content development and are gratefully acknowledged. Members of the WHO Advisory Committee on the Safety of Medicinal Products (ACSoMP) provided guidance at every stage. Marthe Everard, José Luis Castro, Lahouari Belgharbi and Lembit Rägo (WHO) provided useful comments and advice. Shanthi N. Pal (WHO), Sten Olsson (Uppsala Monitoring Centre) and Serge Xueref (consultant) critically reviewed and edited the entire manuscript for technical content and consistency. Susan Kaplan and Geoffrey Bowring (Uppsala Monitoring Centre) edited the publication for grammar and for conformity with WHO house style. Leticia Megias Lastra (consultant) assisted with the cover photographs.

Abbreviations

ADR	adverse drug reaction
ACSoMP	Advisory Committee on Safety of Medicinal Products
CP	core process indicator
CST	core structural indicator
HCP	health-care provider
ICSR	individual case safety report
PSUR	periodic safety update report
MAH	marketing authorization holders
QPPV	qualified person for pharmacovigilance
UMC	Uppsala Monitoring Centre
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27607

